These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15855480)

  • 21. Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy.
    Saladini F; Vicenti I; Razzolini F; Zazzi M
    Clin Microbiol Infect; 2010 Jul; 16(7):848-51. PubMed ID: 19681953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A fossil record of zidovudine resistance in transmitted isolates of HIV-1.
    Kuritzkes DR
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13485-7. PubMed ID: 11717419
    [No Abstract]   [Full Text] [Related]  

  • 24. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
    Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
    Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA; Demeter LM
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current insights into reverse transcriptase inhibitor-associated resistance.
    Wainberg MA; White AJ
    Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
    [No Abstract]   [Full Text] [Related]  

  • 28. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
    Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
    J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.
    Winters MA; Coolley KL; Girard YA; Levee DJ; Hamdan H; Shafer RW; Katzenstein DA; Merigan TC
    J Clin Invest; 1998 Nov; 102(10):1769-75. PubMed ID: 9819361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotype and antiretroviral drug resistance of human immunodeficiency virus-1 in Saudi Arabia.
    Jamjoom GA; Azhar EI; Madani TA; Hindawi SI; Bakhsh HA; Damanhouri GA
    Saudi Med J; 2010 Sep; 31(9):987-92. PubMed ID: 20844809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates.
    Rezende LF; Prasad VR
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1716-34. PubMed ID: 15183340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV drug resistance.
    Clavel F; Hance AJ
    N Engl J Med; 2004 Mar; 350(10):1023-35. PubMed ID: 14999114
    [No Abstract]   [Full Text] [Related]  

  • 33. The clinical significance of viral fitness.
    Geretti AM
    J HIV Ther; 2005 Mar; 10(1):6-10. PubMed ID: 15951728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
    Chiappini E; Galli L; Zazzi M; de Martino M
    J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population.
    Pillay D
    Antivir Ther; 2001; 6 Suppl 3():15-24. PubMed ID: 11678470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.
    Parkin NT; Gupta S; Chappey C; Petropoulos CJ
    Antimicrob Agents Chemother; 2006 Jan; 50(1):351-4. PubMed ID: 16377709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant.
    Chetchotisakd P; Anunnatsiri S; Kiertiburanakul S; Sutthent R; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Horsakulthai M; Chasombat S; Ruxrungtham K;
    J Int Assoc Physicians AIDS Care (Chic); 2006 Dec; 5(4):152-6. PubMed ID: 17101807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences between semen and plasma of nucleoside reverse transcriptase resistance mutations in HIV-infected patients, using a rapid assay.
    Liuzzi G; Chirianni A; Zaccarelli M; Zinzi D; Esposito V; Guadagnino V; Antinori A; Piazza M
    In Vivo; 2004; 18(4):509-12. PubMed ID: 15369193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.
    Descamps D; Chaix ML; Montes B; Pakianather S; Charpentier C; Storto A; Barin F; Dos Santos G; Krivine A; Delaugerre C; Izopet J; Marcelin AG; Maillard A; Morand-Joubert L; Pallier C; Plantier JC; Tamalet C; Cottalorda J; Desbois D; Calvez V; Brun-Vezinet F; Masquelier B; Costagliola D;
    J Antimicrob Chemother; 2010 Dec; 65(12):2620-7. PubMed ID: 20965891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Drug clinics. How I treat HIV infections. II. Nucleoside reverse transcriptase inhibitors].
    Moutschen M; Nkoghe D; Léonard P; Demonty J
    Rev Med Liege; 1997 Dec; 52(12):750-2. PubMed ID: 9481171
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.